Ims Capital Management Gilead Sciences, Inc. Transaction History

Ims Capital Management

$217 Million
Q2 2024

A detailed history of Ims Capital Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ims Capital Management holds 2,918 shares of GILD stock, worth $257,951. This represents 0.09% of its overall portfolio holdings.

Number of Shares

2,918

Previous 6,623 55.94%

Holding current value

$257,951

Previous $485,000 58.76%

% of portfolio

0.09%

Previous 0.23%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 21, 2024	SELL	$63.15 - $72.88 $233,970 - $270,020	-3,705 Reduced 55.94%	2,918 $200,000
Q1 2024 Jun 12, 2024	BUY	$71.58 - $87.29 $122,401 - $149,265	1,710 Added 34.81%	6,623 $485,000
Q1 2023 Sep 13, 2023	SELL	$77.31 - $88.08 $247,392 - $281,856	-3,200 Reduced 39.44%	4,913 $407,000
Q4 2022 Feb 22, 2023	BUY	$62.32 - $89.47 $199,424 - $286,304	3,200 Added 65.13%	8,113 $696,000
Q3 2022 Nov 17, 2022	SELL	$59.54 - $68.01 $224,465 - $256,397	-3,770 Reduced 43.42%	4,913 $303,000
Q2 2022 Jul 13, 2022	BUY	$57.72 - $65.01 $243,116 - $273,822	4,212 Added 94.21%	8,683 $537,000
Q1 2022 Apr 08, 2022	SELL	$57.92 - $72.58 $12,105 - $15,169	-209 Reduced 4.47%	4,471 $266,000
Q4 2021 Jan 05, 2022	BUY	$64.88 - $73.64 $129 - $147	2 Added 0.04%	4,680 $340,000
Q3 2021 Oct 07, 2021	SELL	$67.69 - $73.03 $28,903 - $31,183	-427 Reduced 8.36%	4,678 $327,000
Q2 2021 Jul 07, 2021	BUY	$63.47 - $69.35 $324,014 - $354,031	5,105 New	5,105 $352,000
Q1 2021 Apr 22, 2021	SELL	$60.0 - $68.46 $355,860 - $406,036	-5,931 Closed	0 $0
Q4 2020 Jan 12, 2021	SELL	$56.65 - $64.55 $468,325 - $533,634	-8,267 Reduced 58.23%	5,931 $346,000
Q3 2020 Nov 05, 2020	BUY	$62.1 - $78.08 $44,525 - $55,983	717 Added 5.32%	14,198 $897,000
Q2 2020 Jul 15, 2020	BUY	$72.34 - $84.0 $145,258 - $168,672	2,008 Added 17.5%	13,481 $1.04 Million
Q1 2020 Apr 03, 2020	BUY	$62.63 - $80.22 $249,392 - $319,436	3,982 Added 53.16%	11,473 $858,000
Q4 2019 Jan 15, 2020	SELL	$61.62 - $67.78 $44,428 - $48,869	-721 Reduced 8.78%	7,491 $487,000
Q3 2019 Oct 09, 2019	SELL	$62.51 - $69.0 $318,488 - $351,555	-5,095 Reduced 38.29%	8,212 $520,000
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $42,442 - $47,594	686 Added 5.44%	13,307 $899,000
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $73,192 - $95,511	-1,209 Reduced 8.74%	12,621 $789,000
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $3,065 - $3,393	-43 Reduced 0.31%	13,830 $0
Q2 2018 Jul 26, 2018	SELL	$64.88 - $75.68 $86,809 - $101,259	-1,338 Reduced 8.8%	13,873 $983,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $186,341 - $218,738	-2,619 Reduced 14.69%	15,211 $1.09 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $1.29 Million - $1.52 Million	17,830	17,830 $1.45 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ims Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Ims Capital Management with notifications on news.

Account

Ims Capital Management Gilead Sciences, Inc. Transaction History